Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A window of opportunity trial for metastatic (WOO-M) pancreatic ductal adenocarcinoma (PDAC): A biomarker discovery platform.
Authors
Charles D. Lopez
Oregon Health and Science University, Portland, OR;
Charles D. Lopez , Adel Kardosh , Emerson Yu-sheng Chen , Guillaume Joe Pegna , Alexander Guimaraes , Bryan Foster , Brian Brinkerhoff , Shaun Goodyear , Erin Taber , Brindha Rajagopalan , Johnson Vo , Kiara Siex , Brett Johnson , Danielle Galipeau , Sidney Huszti , Dove Keith , Brett C. Sheppard , Jonathan Brody , Rosalie C. Sears , Gordon B. Mills
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT04005690
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS781)
DOI
10.1200/JCO.2023.41.4_suppl.TPS781
Abstract #
TPS781
Poster Bd #
Q17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer.
First Author: Helen Mackay
Poster
2019 ASCO Annual Meeting
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
First Author: Zahi Ibrahim Mitri
Poster
2018 ASCO Annual Meeting
NCI 10066: A phase 1 / 2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Michael Cecchini
Poster
2017 ASCO Annual Meeting
A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma.
First Author: Jose A. Lopez-Martin